搜尋
InflaRx NV
IFRX添加自選
2.090USD
-0.080-3.69%
收盤 09-09 16:00（美東）
308.00M總市值
虧損本益比TTM
關於 InflaRx NV 公司
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
InflaRx NV 簡介
公司代碼IFRX
公司名稱InflaRx NV
上市日期Nov 08, 2017
CEORiedemann (Niels C)
員工數量74
證券類型Ordinary Share
年結日Nov 08
公司地址Winzerlaer Str. 2
城市JENA
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Germany
郵編07745
電話493641508180
網址https://www.inflarx.de/
公司代碼IFRX
上市日期Nov 08, 2017
CEORiedemann (Niels C)
InflaRx NV公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
490.05K
+4.52%
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Prof. Niels C. Riedemann, M.D., Ph.D.
Prof. Niels C. Riedemann, M.D., Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Anthony Gibney
Mr. Anthony Gibney
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Camilla Chong
Dr. Camilla Chong
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Derval O'Carroll
Ms. Derval O'Carroll
Senior Vice President, Global Head of Regulatory Affairs and Compliance
Senior Vice President, Global Head of Regulatory Affairs and Compliance
--
--
Ms. Hege Hellstrom
Ms. Hege Hellstrom
Non-Executive Independent Director
Non-Executive Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Nicolas Fulpius
Mr. Nicolas Fulpius
Independent Chairman of the Board
Independent Chairman of the Board
490.05K
+4.52%
Mr. Richard Brudnick
Mr. Richard Brudnick
Non-Executive Independent Director
Non-Executive Independent Director
50.00K
--
Dr. Thomas Taapken
Dr. Thomas Taapken
Chief Financial Officer
Chief Financial Officer
3.50K
--
Prof. Niels C. Riedemann, M.D., Ph.D.
Prof. Niels C. Riedemann, M.D., Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Prof. Renfeng Guo
Prof. Renfeng Guo
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
--
--
Mr. Mark Kubler
Mr. Mark Kubler
Non-Executive Independent Director
Non-Executive Independent Director
--
--
常見問題
InflaRx NV的前五大股東是誰？
InflaRx NV的前五大股東如下：Mr. Nicolas Fulpius
有多少機構持有InflaRx NV(IFRX)的股份？
截至2026Q1，共有82家機構持有InflaRx NV的股份，合計持有的股份價值約為19.59M，占公司總股份的13.30% 。與2025Q4相比，機構持股有所增加，增幅為-4596250.00。